Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4M | -7M | -6M | -4M | -4M |
| EBITDA | 31M | 7M | -4M | -4M | -4M |
| Net Income | 31M | 334K | -4M | -4M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.761
+1.45% today
1Y Change
-29.24%
Window
Jun 20, 2025 → Jun 11, 2026
Coverage: 245 bars · Jun 20, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PharmaCyte Biotech, Inc. (PMCB) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $0.76 and down 29.2% across the available one-year price window (Jun 20, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +277.2%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +277.2%, free cash flow -38.4% with operating margin 0.0% and ROIC -9.9%. Stock Foundry combines PMCB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PMCB
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PMCB Max Drawdown
-46.66%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PMCB and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$3.6M
+16.2% YoY
Free Cash Flow
-$3.3M
+19.1% YoY
Revenue Growth
+0.0%
EPS Growth
+277.2%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -4M | -7M | -6M | -4M | -4M |
| EBITDA | 31M | 7M | -4M | -4M | -4M |
| Net Income | 31M | 334K | -4M | -4M | -4M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 15M | 50M | 68M | 85M | 2M |
| Total Assets | 55M | 60M | 73M | 91M | 7M |
| Total Liabilities | 3M | 20M | 587K | 704K | 725K |
| Shareholder Equity | 52M | 40M | 73M | 90M | 7M |
| Total Debt | 0 | 0 | 0 | 0 | 51K |
| Net Debt | -15M | -50M | -68M | -85M | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+19.1% YoY
Capital Expenditures
0
Free Cash Flow
3M
+19.1% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-7.7%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.